November 2024
1. PEDICELLI A, Afif W
   In active ulcerative colitis, risankizumab induced and maintained remission.
   Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02768.
   

   >> Share

   
   September 2023
2. ROWAN C
   In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk.
   Ann Intern Med. 2023 Sep 5. doi: 10.7326/J23-0069.
   

   >> Share

   
   July 2023
3. AL-JABRI R, Afif W
   In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events.
   Ann Intern Med. 2023;176:JC82.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share